See the published version of this preprint at BMC Infectious Diseases.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
mohammed-Jafar Saffar
Mazandaran University of Medical Sciences
Corresponding Author
ORCiD: https://orcid.org/0000-0002-9335-6262
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: In addition to scheduled 2-doses monovalent measles vaccine (mMV) immunization of Iranian children since 1984, a nationwide campaign of measles-rubella (MR) immunization among 5- 25 years-old population in December 2003 was conducted. From 2004 mMV was replaced with measles- mumps-rubella (MMR) vaccine. Despite a high vaccination coverage, outbreaks of measles occurred in the country. Study was designed to investigate seroimmunity status against measles and rubella among various age groups of population who were vaccinated with different schedule since 1984. Also, immunologic response to revaccination in seronegative subjects was evaluated.
Methods: From 1 November 2017 to 30 June 2018 a cross- sectional study among 7- 33 year old (born 1984-2011) healthy population with documented history of measles vaccination was conducted. Based on their age and history of vaccination status categorized as GA: 20-2333 years old; vaccinated with 1-2 dose of mMV, and also MR revaccinated. GB: 15-19 years, vaccinated only with 2- doses of mMV at the ages of 9 and 15 months and MMR 2-5 years later. GC: 12-14 years and GD: 7-11 years; vaccinated with 2- dose of MMR vaccine at the ages 15 months - 6 years, and 12-18 months respectively. Collected sera were assessed to measure antimeasles and antirubella IgG antibodies concentration. Four to 6 weeks after revaccination of seronegative subjects, antimeasles-antirubella IgM and IgG antibodies were rechecked. Collected data were analyzed using descriptive statistical methods.
Results: Totally 635 individuals, 312 female were included. Relative distribution of subjects in each group was as: GA: 98, GB: 295, GC: 139, and GD: 103 persons. Overall, 12.28% and 18.4% of population were soronegative, and varied greatly between groups: 2%-0/0%, 15.2%- 25.0%, 11.5%- 17.2%; and 14.6%-18.4%, to measles and rubella, respectively. After revaccination, 92% and 94.9% showed 1gG response to measles and rubella vaccine respectively.
Conclusion: Despite high coverage rate with measles and rubella containing vaccine, a significant numbers of vaccinated subjects lost their seroprotection were seronegative, possibly because of secondary vaccine failure. This may affect measles-rubella elimination goal in the country. If these data were confirmed by further studies, more strengthen regional/ national supplementary immunization activity should be considered.
Keywords
Measles, Rubella, MMR, Measles elimination, congenial rubella syndrome, Iran
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Infectious Diseases.
No community comments so far
Editorial decision: Major revision
On 02 Feb, 2021
Review #1 received
Received 14 Jan, 2021
Reviewer #1 agreed
On 27 Dec, 2020
Reviewers invited
Invitations sent on 21 Dec, 2020
Editor assigned
On 16 Dec, 2020
Submission checks complete
On 16 Dec, 2020
Editor invited
On 16 Dec, 2020
Version 2
Posted 23 Oct, 2020
No comments provided
Editorial decision: Major revision
On 08 Nov, 2020
Review #1 received
Received 02 Nov, 2020
Review #3 received
Received 23 Oct, 2020
Reviewer #3 agreed
On 15 Oct, 2020
Reviewer #2 agreed
On 14 Oct, 2020
Review #2 received
Received 14 Oct, 2020
Editor assigned
On 13 Oct, 2020
Reviewers invited
Invitations sent on 13 Oct, 2020
Reviewer #1 agreed
On 13 Oct, 2020
Submission checks complete
On 12 Oct, 2020
Editor invited
On 12 Oct, 2020
No comments provided
Editorial decision: Major revision
On 15 Sep, 2020
Review #3 received
Received 08 Sep, 2020
Review #2 received
Received 31 Aug, 2020
Reviewer #3 agreed
On 17 Aug, 2020
Reviewer #2 agreed
On 14 Aug, 2020
Review #1 received
Received 30 Jul, 2020
Reviewer #1 agreed
On 23 Jul, 2020
Reviewers invited
Invitations sent on 22 Jul, 2020
First submitted
On 02 Jul, 2020
Editor assigned
On 02 Jul, 2020
Submission checks complete
On 01 Jul, 2020
Editor invited
On 01 Jul, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Infectious Diseases.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
mohammed-Jafar Saffar
Mazandaran University of Medical Sciences
Corresponding Author
ORCiD: https://orcid.org/0000-0002-9335-6262
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Infectious Diseases.
No community comments so far
Editorial decision: Major revision
On 02 Feb, 2021
Review #1 received
Received 14 Jan, 2021
Reviewer #1 agreed
On 27 Dec, 2020
Reviewers invited
Invitations sent on 21 Dec, 2020
Editor assigned
On 16 Dec, 2020
Submission checks complete
On 16 Dec, 2020
Editor invited
On 16 Dec, 2020
Version 2
Posted 23 Oct, 2020
No comments provided
Editorial decision: Major revision
On 08 Nov, 2020
Review #1 received
Received 02 Nov, 2020
Review #3 received
Received 23 Oct, 2020
Reviewer #3 agreed
On 15 Oct, 2020
Reviewer #2 agreed
On 14 Oct, 2020
Review #2 received
Received 14 Oct, 2020
Editor assigned
On 13 Oct, 2020
Reviewers invited
Invitations sent on 13 Oct, 2020
Reviewer #1 agreed
On 13 Oct, 2020
Submission checks complete
On 12 Oct, 2020
Editor invited
On 12 Oct, 2020
No comments provided
Editorial decision: Major revision
On 15 Sep, 2020
Review #3 received
Received 08 Sep, 2020
Review #2 received
Received 31 Aug, 2020
Reviewer #3 agreed
On 17 Aug, 2020
Reviewer #2 agreed
On 14 Aug, 2020
Review #1 received
Received 30 Jul, 2020
Reviewer #1 agreed
On 23 Jul, 2020
Reviewers invited
Invitations sent on 22 Jul, 2020
First submitted
On 02 Jul, 2020
Editor assigned
On 02 Jul, 2020
Submission checks complete
On 01 Jul, 2020
Editor invited
On 01 Jul, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Infectious Diseases.
Background: In addition to scheduled 2-doses monovalent measles vaccine (mMV) immunization of Iranian children since 1984, a nationwide campaign of measles-rubella (MR) immunization among 5- 25 years-old population in December 2003 was conducted. From 2004 mMV was replaced with measles- mumps-rubella (MMR) vaccine. Despite a high vaccination coverage, outbreaks of measles occurred in the country. Study was designed to investigate seroimmunity status against measles and rubella among various age groups of population who were vaccinated with different schedule since 1984. Also, immunologic response to revaccination in seronegative subjects was evaluated.
Methods: From 1 November 2017 to 30 June 2018 a cross- sectional study among 7- 33 year old (born 1984-2011) healthy population with documented history of measles vaccination was conducted. Based on their age and history of vaccination status categorized as GA: 20-2333 years old; vaccinated with 1-2 dose of mMV, and also MR revaccinated. GB: 15-19 years, vaccinated only with 2- doses of mMV at the ages of 9 and 15 months and MMR 2-5 years later. GC: 12-14 years and GD: 7-11 years; vaccinated with 2- dose of MMR vaccine at the ages 15 months - 6 years, and 12-18 months respectively. Collected sera were assessed to measure antimeasles and antirubella IgG antibodies concentration. Four to 6 weeks after revaccination of seronegative subjects, antimeasles-antirubella IgM and IgG antibodies were rechecked. Collected data were analyzed using descriptive statistical methods.
Results: Totally 635 individuals, 312 female were included. Relative distribution of subjects in each group was as: GA: 98, GB: 295, GC: 139, and GD: 103 persons. Overall, 12.28% and 18.4% of population were soronegative, and varied greatly between groups: 2%-0/0%, 15.2%- 25.0%, 11.5%- 17.2%; and 14.6%-18.4%, to measles and rubella, respectively. After revaccination, 92% and 94.9% showed 1gG response to measles and rubella vaccine respectively.
Conclusion: Despite high coverage rate with measles and rubella containing vaccine, a significant numbers of vaccinated subjects lost their seroprotection were seronegative, possibly because of secondary vaccine failure. This may affect measles-rubella elimination goal in the country. If these data were confirmed by further studies, more strengthen regional/ national supplementary immunization activity should be considered.
Loading...